Evidence map›Paper›PMID 34009266›Full record

ArticleBriefings in bioinformatics2021

DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity.

Guangyuan Li, Balaji Iyer, V B Surya Prasath, Yizhao Ni, Nathan Salomonis

Open access · hybridAbstract read
In one paragraph

Article in Briefings in bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. AI snake oil? A risk/benefit analysis for toxicology.Frontiers in artificial intelligence · 2026
    Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Guangyuan LiUniversity of Cincinnati, 3333 Burnet Ave, MLC7024, Cincinnati, OH 45267, USA.
Balaji IyerUniversity of Cincinnati, USA.
V B Surya PrasathBiomedical Informatics, Cincinnati Children's Hospital Medical Center, USA.
Yizhao NiCincinnati Children's Hospital Medical Center, USA.
Nathan SalomonisCincinnati Children's Hospital Medical Center, USA.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · US

Funding

Unbiased identification of spliceosome vulnerabilities across cancerR01CA226802 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI SALOMONIS, NATHAN G. · 2018 to 2022
$2.4M
Cincinnati Children's Hospital Research FoundationNCI NIH HHS R01 CA226802NIH HHS R01CA226802
6 · The paper itself

Abstract

Cytolytic T-cells play an essential role in the adaptive immune system by seeking out, binding and killing cells that present foreign antigens on their surface. An improved understanding of T-cell immunity will greatly aid in the development of new cancer immunotherapies and vaccines for life-threatening pathogens. Central to the design of such targeted therapies are computational methods to predict non-native peptides to elicit a T-cell response, however, we currently lack accurate immunogenicity inference methods. Another challenge is the ability to accurately simulate immunogenic peptides for specific human leukocyte antigen alleles, for both synthetic biological applications, and to augment real training datasets. Here, we propose a beta-binomial distribution approach to derive peptide immunogenic potential from sequence alone. We conducted systematic benchmarking of five traditional machine learning (ElasticNet, K-nearest neighbors, support vector machine, Random Forest and AdaBoost) and three deep learning models (convolutional neural network (CNN), Residual Net and graph neural network) using three independent prior validated immunogenic peptide collections (dengue virus, cancer neoantigen and SARS-CoV-2). We chose the CNN as the best prediction model, based on its adaptivity for small and large datasets and performance relative to existing methods. In addition to outperforming two highly used immunogenicity prediction algorithms, DeepImmuno-CNN correctly predicts which residues are most important for T-cell antigen recognition and predicts novel impacts of SARS-CoV-2 variants. Our independent generative adversarial network (GAN) approach, DeepImmuno-GAN, was further able to accurately simulate immunogenic peptides with physicochemical properties and immunogenicity predictions similar to that of real antigens. We provide DeepImmuno-CNN as source code and an easy-to-use web interface.

Indexed as

AlgorithmsCOVID-19Deep LearningHumansMachine LearningNeural Networks, ComputerPeptidesSARS-CoV-2SoftwareT-LymphocytesPeptidesconvolutional neural networkCOVID-19deep learninggenerative adversarial networkimmunogenicityneoantigen

Identifiers

PMID34009266
PMCPMC8135853
OpenAlexW3159295432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.